Want to see HK:2005 full AI Analyst Report?
Top Page
SSY Group
(2005)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$3.00
▲(11.94% Upside)
Action:Reiterated
Date:06/24/26
The score is driven primarily by mixed financial performance: a historically solid profile but a meaningful 2025 reset in revenue, margins, and returns. Technicals are a major headwind with clear bearish trend signals across moving averages and MACD. Valuation and dividend yield are supportive, helping partially offset the weaker fundamentals and momentum.
Positive Factors
Manageable Leverage
Controlled leverage and a substantial equity base provide financial resilience as the company navigates weaker profitability. This balance-sheet position preserves capacity to fund operations, absorb earnings volatility, and pursue investment without excessive debt pressure.
Negative Factors
Revenue Contraction
The decline in revenue signals weaker demand or business activity and reduces the base from which future earnings can grow. If contraction persists, it could limit operating leverage, constrain investment capacity, and make recovery in profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Controlled leverage and a substantial equity base provide financial resilience as the company navigates weaker profitability. This balance-sheet position preserves capacity to fund operations, absorb earnings volatility, and pursue investment without excessive debt pressure.
Read all positive factors
SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$8.06B
Dividend Yield2.92%
Average Volume (3M)3.81M
Price to Earnings (P/E)15.7
Beta (1Y)0.68
Revenue Growth-4.42%
EPS Growth-21.96%
CountryHK
Employees5,472
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,951,113,300
10 Day Avg. Volume6,137,013
30 Day Avg. Volume3,812,958
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.14
Price to Sales (P/S)1.99
P/FCF Ratio27.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.93Price Target Upside46.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SSY Group Business Overview & Revenue Model
Company Description
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally. The company offers intr...
SSY Group Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
70
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.38B | 4.17B | 5.77B | 6.46B | 6.43B | 5.36B |
| Gross Profit | 1.75B | 1.73B | 2.91B | 3.62B | 3.44B | 3.04B |
| EBITDA | 1.06B | 1.04B | 1.74B | 2.11B | 1.86B | 1.40B |
| Net Income | 507.45M | 470.64M | 1.06B | 1.32B | 1.12B | 785.53M |
Balance Sheet | ||||||
| Total Assets | 13.47B | 12.81B | 12.60B | 11.97B | 10.97B | 10.71B |
| Cash, Cash Equivalents and Short-Term Investments | 1.97B | 1.82B | 1.29B | 1.62B | 1.71B | 1.70B |
| Total Debt | 4.05B | 4.01B | 3.64B | 3.37B | 3.21B | 3.11B |
| Total Liabilities | 5.33B | 5.19B | 5.07B | 4.70B | 4.42B | 4.22B |
| Stockholders Equity | 7.80B | 7.30B | 7.22B | 6.93B | 6.21B | 6.22B |
Cash Flow | ||||||
| Free Cash Flow | 501.57M | 299.78M | -49.39M | 221.88M | 368.70M | 359.58M |
| Operating Cash Flow | 442.03M | 635.03M | 491.03M | 925.75M | 786.82M | 747.91M |
| Investing Cash Flow | 135.81M | 77.02M | -521.76M | -640.19M | -402.72M | -681.23M |
| Financing Cash Flow | -285.46M | -293.69M | -295.42M | -304.57M | -190.51M | 136.13M |
SSY Group Technical Analysis
Positive
2.68
Price Trends
2.45
Positive
2.38
Positive
2.59
Positive
Market Momentum
0.09
Negative
76.54
Negative
85.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2005, the sentiment is Positive. The current price of 2.68 is above the 20-day moving average (MA) of 2.56, above the 50-day MA of 2.45, and above the 200-day MA of 2.59, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 76.54 is Negative, neither overbought nor oversold. The STOCH value of 85.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2005.
SSY Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$779.10M | 7.81 | 13.59% | 7.40% | 10.63% | 39.44% | |
77 Outperform | HK$6.24B | 6.74 | 9.81% | 7.41% | -17.74% | 1.12% | |
59 Neutral | HK$8.06B | 15.68 | 6.72% | 2.92% | -4.42% | -21.96% | |
59 Neutral | HK$1.48B | 5.53 | 6.78% | 9.60% | 6.55% | 36.62% | |
53 Neutral | HK$6.77B | -5.58 | -4.98% | 0.26% | -15.80% | -298.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$339.89M | 84.72 | 0.34% | 84.69% | -8.30% | -44.44% |
* Healthcare Sector Average
HK:2005
SSY Group
2.74
-0.28
-9.27%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.34
-0.84
-38.48%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.04
-10.29%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.00
-0.17
-14.60%
HK:0239
Pak Fah Yeow International Limited
2.50
0.23
10.33%
HK:2877
China Shineway Pharmaceutical Group Limited
8.19
-0.11
-1.34%
SSY Group Corporate Events
SSY Group Buys 1 Million Shares for Employee Award Scheme
Sep 3, 2026
SSY Group Limited has announced that the trustee of its Restricted Share Award Scheme purchased 1,000,000 shares on the open market on 3 September 2026, funded by the company’s internal resources, at an average price of about HK$2.754 per sh...
SSY Group Boosts Staff Incentive Pool With Open-Market Share Purchase
Sep 2, 2026
SSY Group Limited has announced that the trustee of its Restricted Share Award Scheme purchased 1,200,000 shares on the open market on 2 September 2026, funded by the company’s internal resources. The purchase represents approximately 0.041%...
SSY Group Wins Key Approval for Diltiazem Cardiovascular Portfolio in China
Sep 2, 2026
SSY Group Limited has secured approval from China’s National Medical Products Administration for the consistency evaluation of the quality and efficacy of its Diltiazem Hydrochloride Tablets, its third such approval among its PRC entities. T...
SSY Group Expands Restricted Share Award Scheme with Market Buyback
Sep 1, 2026
SSY Group Limited has expanded its restricted share award scheme by funding the purchase of 1,000,000 shares on the open market, to be held in trust for selected participants under the plan. The acquisition, completed on 1 September 2026 at an ave...
SSY Group Boosts Restricted Share Pool With Market Buyback for Incentive Scheme
Aug 31, 2026
SSY Group Limited has disclosed that the trustee of its restricted share award scheme purchased 900,000 shares on the open market on 31 August 2026, funded entirely by the company’s internal resources and representing about 0.030% of its iss...
SSY Group Wins China Approvals for Two Key Diagnostic Injectables
Aug 27, 2026
SSY Group has secured approval from China’s National Medical Products Administration for production and registration of its Gadobutrol Injection, a next-generation macrocyclic MRI contrast agent for adults and children, completing an integra...
SSY Group Delivers Profit Growth and Higher Dividend Amid Sector Reforms
Aug 26, 2026
SSY Group reported steady growth for the six months to 30 June 2026, navigating a complex macroeconomic backdrop and ongoing reforms in China’s pharmaceutical sector, including centralised procurement and shifting healthcare insurance polici...
SSY Group Declares Interim Cash Dividend for First Half of 2026
Aug 26, 2026
SSY Group Limited has declared an interim ordinary cash dividend of HKD 0.055 per share for the six months ended 30 June 2026, payable in Hong Kong dollars without withholding tax. The ex-dividend date is set for 10 September 2026, with the record...
SSY Group Secures Approval for New Ozagrel Injection to Bolster Neurology Portfolio
Aug 25, 2026
SSY Group Limited, a China-focused pharmaceutical manufacturer, has expanded its neurology franchise built around ozagrel-based treatments used in hospital and specialist settings. The company previously marketed ozagrel sodium chloride intravenou...
SSY Group Wins China Approval for Vitamin K1 Injection
Aug 20, 2026
SSY Group Limited has received approval from China’s National Medical Products Administration for production and registration of its Vitamin K1 Injection, which has passed consistency evaluation. The injectable is indicated for treating and ...
SSY Group Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 14, 2026
SSY Group Limited has scheduled a board meeting for 26 August 2026 to approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also review whether to recommend an interim dividend, highlighting the company̵...
SSY Group Wins China Approval for New Antipsychotic Bulk Drug
Aug 7, 2026
SSY Group Limited has secured approval from China’s National Medical Products Administration for its Ziprasidone Hydrochloride to be registered as a bulk drug used in market preparations, expanding its presence in second-generation antipsych...
SSY Group Wins NMPA Approvals for Four New Drugs, Bolsters Ophthalmic and ICU Portfolios
Aug 6, 2026
SSY Group has secured approvals from China’s National Medical Products Administration for four new drugs, all deemed to have passed consistency evaluation, marking an expansion of its regulated product line. The newly cleared products includ...
SSY Group Wins Full Slate of Bids in China’s 12th National Drug Procurement Round
Aug 3, 2026
SSY Group Limited announced that all 13 products with 16 specifications it submitted for the twelfth batch of China’s National Centralised Medicines Procurement were successfully selected, covering a range of tablets, capsules and injections...
SSY Group Wins NMPA Approval for New Gastrointestinal and Respiratory Drugs
Jul 30, 2026
SSY Group has received approval from China’s National Medical Products Administration for the production and registration of its Cimetidine Injection, a type 3 chemical drug used primarily in the treatment of digestive tract ulcers. The prod...
SSY Group Wins Approval for Four New Drugs, Expands Critical Care and Ophthalmic Portfolio
Jul 23, 2026
SSY Group Limited has received Chinese regulatory approval for four type 4 chemical drugs, strengthening its portfolio across critical care, cardiovascular, ophthalmic and parenteral nutrition segments. The new products include a hemofiltration re...
SSY Group Wins China Approval for Next-Generation MRI Contrast Agent Gadobutrol
Jul 21, 2026
SSY Group Limited has secured registration approval from China’s National Medical Products Administration for Gadobutrol as a bulk drug, clearing the way for its use in market-ready preparations. The magnetic resonance imaging contrast agent...
SSY Group Wins China Approval for Next-Generation Lipid-Lowering Capsule
Jul 16, 2026
SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register its Choline Fenofibrate Sustained-release Capsules (135mg), classified as a type 4 chemical drug and recognized as having p...
SSY Group Wins NMPA Approval for Baloxavir Marboxil Bulk Drug in China
Jul 13, 2026
SSY Group has secured approval from China’s National Medical Products Administration for its Baloxavir Marboxil as a bulk drug for marketed preparations, making it the third such approval granted to a PRC entity. The antiviral, indicated for...
SSY Group Gains New NMPA Approvals for Hyperthyroidism and Calcium Therapies
Jul 10, 2026
SSY Group has received Chinese regulatory approval for the production and registration of its Propylthiouracil Tablets, a type 4 chemical drug used to treat various forms of hyperthyroidism in patients who cannot tolerate methimazole. The approval...
SSY Group Gains Major Boost as 95 Drugs Enter China’s 2026 Essential Medicines List
Jul 10, 2026
SSY Group Limited, a Hong Kong-listed pharmaceutical manufacturer, produces a wide range of injectable and oral drugs for the Chinese healthcare system, including antibiotics, chronic disease treatments and respiratory medications. Its diversified...
SSY Group Wins NMPA Approvals for Methocarbamol Tablets and Phloroglucinol Bulk Drug
Jul 2, 2026
SSY Group has become the first entity in mainland China to secure National Medical Products Administration approval for the production and registration of 0.5g Methocarbamol Tablets, a muscle relaxant used to treat joint and muscle sprains, lumbar...
SSY Group Expands Restricted Share Award Pool with Market Purchase
Jun 26, 2026
SSY Group has activated its restricted share award scheme by instructing the scheme trustee to purchase 600,000 shares on the open market on 26 June 2026, funded by internal resources. The purchase represents about 0.02% of the company’s iss...
SSY Group Buys Back 1 Million Shares for Restricted Award Scheme
Jun 25, 2026
SSY Group Limited has repurchased 1,000,000 of its own shares on the open market under its Restricted Share Award Scheme, using internal resources to fund the transaction. The shares, bought on 25 June 2026 at an average price of about HK$2.1512 e...
SSY Group Boosts Share Award Pool with Open-Market Purchase
Jun 24, 2026
SSY Group has executed a share purchase on the open market under its Restricted Share Award Scheme, with the scheme trustee acquiring 1,000,000 shares on 24 June 2026 using the company’s internal resources. The newly purchased shares, repres...
SSY Group Buys Back 2 Million Shares for Employee Award Scheme
Jun 23, 2026
SSY Group has repurchased 2,000,000 of its own shares on the open market through a trustee under its Restricted Share Award Scheme adopted in December 2018. The purchase, completed on 23 June 2026 and funded by internal resources, represents about...
SSY Group Wins NMPA Approvals for Parkinson’s and Respiratory Drugs
Jun 22, 2026
SSY Group has secured approval from China’s National Medical Products Administration for the production and registration of Safinamide Mesylate Tablets in 50mg and 100mg strengths, classified as a type 4 chemical drug and deemed to have pass...
SSY Group Adds Shares to Restricted Award Scheme via Market Purchase
Jun 17, 2026
SSY Group Limited has disclosed that the trustee of its Restricted Share Award Scheme purchased 380,000 shares on the open market on 17 June 2026, funded by the company’s internal resources. The acquisition, representing about 0.013% of issu...
SSY Group Expands Pool of Shares for Restricted Award Scheme via Market Purchase
Jun 16, 2026
SSY Group Limited has moved to strengthen its employee incentive framework under its Restricted Share Award Scheme by directing a scheme trustee to purchase 1,000,000 shares on the open market on 16 June 2026. The shares, funded entirely from inte...
SSY Group Wins China Approval for New Cefpodoxime Suspension
Jun 16, 2026
SSY Group Limited has secured approval from China’s National Medical Products Administration to produce and register Cefpodoxime Proxetil for Suspension (50mg), a type 3 chemical drug that has passed consistency evaluation. The antibiotic is...
SSY Group Boosts Restricted Share Award Holdings With HK$2.28 Million Share Purchase
Jun 15, 2026
SSY Group has disclosed that the trustee of its Restricted Share Award Scheme purchased 1,000,000 shares on the open market on 15 June 2026, representing about 0.034% of its issued share capital. Funded entirely by internal resources at an average...
SSY Group Secures Exclusive China Rights to Innovative Peritoneal Dialysis Drug OPT101
Jun 15, 2026
SSY Group’s wholly owned unit Shijiazhuang No. 4 Pharmaceutical has signed a non-binding letter of intent with Swiss biopharmaceutical company Opterion Health AG for an exclusive licence to develop, manufacture and sell OPT101 in mainland Ch...
SSY Group Boosts Employee Incentive Pool with Open-Market Share Purchase
Jun 12, 2026
SSY Group Limited has expanded its equity-based incentive programme under its Restricted Share Award Scheme by directing a trustee to purchase 2,000,000 shares on the open market on 12 June 2026. The shares, representing about 0.068% of the existi...
SSY Group Wins Approval as Marketing Authorization Holder for Key Injectable Antibiotic
Jun 8, 2026
SSY Group Limited has received approval from China’s National Medical Products Administration to become the marketing authorization holder for Ceftizoxime Sodium for Injection in 1g and 0.5g dosages. The antibiotic is indicated for a wide ra...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.